Phillip Koo:

You talked about sort of these doublets and triplets. Even within these doublets and triplets, we have multiple different options for the type of what we call “ARPI drugs” that you could use. You know, abiraterone, enzalutamide, darolutamide, and whatnot.  How do you decide which one gets combined?

Zachary Klaassen:

Yeah, it's a great question. There's never been a head-to-head trial. So when we look at these options, we can't say one's better than the other, what it typically comes down to–and they all work very well. So I think the message is, the doublets work great, no matter which one you're on. There's a few nuances in terms of side effect profiles with some of these, so that may come into it a little bit. There's some drugs that are a little bit better or easier to use in combination with other medicines, that many of these men are on, such as antithrombotics or blood thinners or cholesterol medicine, so that may come into a little bit as well, too.

And then it's probably a little bit just what the physician's preferences are. I think that's fair as well. They have more experience with one versus the other, they may be a little more apt to use it. The answer is, there's no head-to-head trial, so we can't say one's better. But there's nuances to say, “Maybe this patient's a little bit better for this treatment versus this treatment.”

Phillip Koo:

Great, and I think that's a conversation that you know patients should have with their physician.